A new medication was recently approved by the FDA for migraine sufferers. According to the FDA, Aimovig is the first in a new class of drugs “that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.”
An article published in Science News explains what is known – and what is still unknown – about this new medication. You can read the summary below or by clicking here.
Print this page